On the short arm of chromosome 1, at position 1p36, two genes sit in close proximity with distinct but complementary roles in immune homeostasis: MMEL1, encoding a neprilysin-like metalloendopeptidase, and TNFRSF14, encoding HVEM¹¹ HVEM
Herpes Virus Entry Mediator, also known as CD270 — a TNF receptor superfamily member that regulates both activating and inhibitory T-cell signals. The rs3890745 intronic SNP²² SNP
Single nucleotide polymorphism — a single-letter DNA difference that varies between people; this one lies within MMEL1 but is in linkage disequilibrium with regulatory elements affecting both neighboring genes has been consistently associated with rheumatoid arthritis susceptibility in multiple genome-wide association studies. The C allele, carried at approximately 32% frequency in Europeans but up to 53% in African populations, tags a risk haplotype at this locus.

The Mechanism

rs3890745 falls within an intron of MMEL1 (membrane metalloendopeptidase like 1), also known as NEP2 or neprilysin II. MMEL1 is a zinc-dependent neutral endopeptidase that cleaves bioactive peptides including neuropeptides and inflammatory mediators — a function that positions it as a regulator of local peptide signaling in immune and neural contexts. MMEL1 is expressed broadly, with highest levels in testis and small intestine, and weaker expression in brain, kidney, and immune tissues.

The more immunologically prominent neighbor is TNFRSF14 (HVEM/CD270). HVEM operates as a dual-function immune checkpoint: it can deliver activating signals to T cells via binding LIGHT³³ LIGHT
TNFSF14, a ligand expressed on activated T cells that delivers costimulatory signals through HVEM, promoting T-cell proliferation and cytokine production, but it also transmits inhibitory signals through BTLA⁴⁴ inhibitory signals through BTLA
B- and T-lymphocyte attenuator — an inhibitory receptor expressed on lymphocytes that signals "stop" when bound to HVEM, analogous to CTLA-4 and PD-1. This bidirectional control makes HVEM a critical rheostat in peripheral immune tolerance. Disruption of the HVEM/BTLA inhibitory axis has been implicated in multiple autoimmune conditions, including rheumatoid arthritis, celiac disease, and inflammatory bowel disease.

As an intronic variant, rs3890745 does not change the MMEL1 protein sequence. It is presumed to act as a regulatory tag SNP in linkage disequilibrium with functional variants that alter expression levels of MMEL1, TNFRSF14, or both in immune cell populations. Expression quantitative trait locus (eQTL) data from immune cells would be required to identify the precise causal variant; the rs3890745 association most likely reflects a haplotype-level regulatory effect spanning both genes.

The Evidence

The MMEL1-TNFRSF14 locus was first established as an RA susceptibility region in a 2008 genome-wide association meta-analysis⁵⁵ genome-wide association meta-analysis
Study design combining multiple GWAS cohorts to increase statistical power — more samples yield more reliable effect estimates by Raychaudhuri and colleagues (Nature Genetics), which analyzed 3,393 cases and 12,462 controls in the discovery phase and 3,929 anti-CCP-positive RA cases and 5,807 controls in replication. The rs3890745 signal at this locus reached an overall p-value of 1.1×10⁻⁷, placing it among confirmed RA susceptibility loci alongside CD40, KIF5A, and CDK6.

The association was replicated in the large trans-ethnic RA GWAS meta-analysis⁶⁶ large trans-ethnic RA GWAS meta-analysis
Trans-ethnic meta-analysis pooling cohorts of European, East Asian, and mixed ancestry — improves fine-mapping precision by narrowing LD blocks by Okada et al. (Nature, 2014), which confirmed an odds ratio of 1.18 (95% CI 1.10–1.27) for the risk allele at this locus. An independent GWAS meta-analysis by Stahl et al. (Nature Genetics, 2010)⁷⁷ Stahl et al. (Nature Genetics, 2010)
Discovery phase: 5,539 RA cases and 20,169 controls from European populations; replication phase: 6,768 cases and 8,806 controls confirmed the MMEL1 locus at p=4×10⁻⁶. A 2019 cross-trait GWAS analysis⁸⁸ 2019 cross-trait GWAS analysis
Examining shared genetic architecture between autoimmune diseases and non-Hodgkin lymphomas using regional overlap and polygenic risk scores identified rs3890745 with OR 1.14 at genome-wide significance (p=2×10⁻⁸) in a combined RA/DLBCL analysis, supporting shared immune-regulatory genetic architecture across B-cell-driven conditions.

Beyond RA, variants at the MMEL1-TNFRSF14 locus have been associated with multiple sclerosis and primary biliary cirrhosis in separate GWAS, consistent with the broad role of HVEM-mediated immune costimulation in peripheral tolerance across different autoimmune phenotypes.

The per-allele odds ratio of approximately 1.12–1.18 classifies this as a moderate-effect susceptibility locus. This is consistent with the polygenic architecture of RA, where dozens of loci each contribute small incremental risk — the clinical impact of rs3890745 alone is modest, but it gains significance when combined with high-risk HLA-DRB1 shared epitope alleles or PTPN22 R620W.

Practical Actions

For C allele carriers, particularly CC homozygotes, the priority is early recognition of seropositive RA — the anti-CCP (ACPA)-positive, erosive subtype with the strongest genetic component. Because rs3890745 tags shared autoimmune genetic architecture, individuals with joint symptoms, unexplained morning stiffness, or a strong family history of RA should prioritize early autoantibody testing. Vitamin D3 supplementation has demonstrated a 22% reduction in incident autoimmune disease in the VITAL RCT and acts as a direct NF-kB and T-cell regulatory modulator.

Interactions

rs3890745 sits in the same chromosomal neighbourhood as a broader 1p36 autoimmune risk region. TNFRSF14/HVEM interacts directly with BTLA on T cells and B cells — variants in the BTLA locus (rs9288952) have been associated with RA in some GWAS, suggesting a potential compound effect through the HVEM-BTLA inhibitory axis. MMEL1 has homology with neprilysin (NEP/CD10), which processes inflammatory neuropeptides; the folate-methylation pathway (MTHFR, rs1801133) intersects with DNA methylation patterns at immune loci that regulate TNFRSF14 expression.

The strongest RA risk loci that may compound with rs3890745 include PTPN22 rs2476601 (T-cell signaling threshold), TRAF1-C5 rs10818488 (NF-kB regulation), and HLA-DRB1 shared epitope alleles (antigen presentation). These operate through distinct pathways and their combined carriage incrementally raises absolute RA risk.

Your body's natural killer (NK) cells carry a surface receptor called FcgammaRIIIa (CD16a)¹¹ FcgammaRIIIa (CD16a)
The primary Fc receptor on NK cells that binds the constant region of IgG antibodies, triggering antibody-dependent cellular cytotoxicity that connects innate immunity to antibody-mediated defense. This receptor grabs the tail end of IgG antibodies already bound to target cells — infected cells, cancer cells, or cells flagged for destruction — and activates the NK cell to kill. The V158F variant (rs396991) changes a single amino acid in the IgG-binding domain of this receptor, creating two versions with dramatically different binding affinities²² dramatically different binding affinities
The 158V isoform binds IgG1 and IgG3 with approximately 2-fold higher affinity than the 158F isoform. This difference matters both for natural immune surveillance and, critically, for how well monoclonal antibody therapies work.

Genotyping accuracy warning: FCGR3A shares over 98% sequence homology³³ over 98% sequence homology
Only four nucleotides differ between FCGR3A and FCGR3B in the genotyped region with its neighboring gene FCGR3B. This extreme similarity can cause consumer genotyping chips and some research assays to inadvertently read FCGR3B sequence instead of FCGR3A, producing incorrect genotype calls. Validated TaqMan assays show 100% accuracy in European and Asian populations but 7.8% error rate in African populations and 1.1% in admixed American populations⁴⁴ 7.8% error rate in African populations and 1.1% in admixed American populations. If your result seems inconsistent with clinical observations, consider confirmatory testing with a gene-specific assay.

The Mechanism

The FCGR3A gene encodes a transmembrane glycoprotein expressed primarily on NK cells, macrophages, and some T-cell subsets. The V158F polymorphism occurs in the second extracellular immunoglobulin-like domain⁵⁵ second extracellular immunoglobulin-like domain
This domain directly contacts the CH2 region of IgG, and the amino acid at position 158 sits at the binding interface, precisely where IgG makes contact. Valine at position 158 (encoded by the C allele on the plus strand) creates a receptor that binds IgG1 and IgG3 with approximately two-fold higher affinity than phenylalanine at the same position (A allele). This translates directly into enhanced antibody-dependent cellular cytotoxicity (ADCC)⁶⁶ enhanced antibody-dependent cellular cytotoxicity (ADCC)
ADCC is the process by which NK cells kill antibody-coated target cells; higher receptor affinity means more efficient target recognition and killing.

The functional hierarchy is clear: V/V homozygotes show the strongest ADCC activity, V/F heterozygotes are intermediate, and F/F homozygotes have the weakest response. This gradient affects both natural immune surveillance against infected or abnormal cells and the therapeutic efficacy of monoclonal antibodies that depend on ADCC as their mechanism of action.

The Evidence

Monoclonal Antibody Therapy

The pharmacogenomic significance of V158F was first demonstrated in follicular lymphoma patients treated with rituximab⁷⁷ follicular lymphoma patients treated with rituximab
Cartron et al. showed V/V patients achieved significantly higher molecular response rates to rituximab monotherapy than V/F or F/F patients. For trastuzumab in HER2-positive breast cancer, a study of Egyptian patients⁸⁸ study of Egyptian patients
V/V genotype present in 29.6% of responders vs 8.4% of non-responders; median progression-free survival 22 months for V/V vs 6 months for F/F (p=0.003) found V/V carriers had significantly better overall survival and response rates. In follicular lymphoma treated with antibody-chemotherapy combinations⁹⁹ follicular lymphoma treated with antibody-chemotherapy combinations
SWOG trials showed patients with at least one V allele had better overall survival than F/F patients when treated with antibody-chemotherapy combinations, V allele carriers showed improved outcomes specifically in the antibody-containing treatment arms.

However, results are not universally consistent. A large randomized study in follicular lymphoma¹⁰¹⁰ A large randomized study in follicular lymphoma
Analysis of 321 patients found no FCGR genotype predicted initial response to rituximab or rituximab-chemotherapy combinations found no predictive value, highlighting that tumor biology, immune microenvironment, and combination chemotherapy may modulate the receptor's influence. The evidence is strongest for rituximab monotherapy and weakens when combined with intensive chemotherapy regimens.

Anti-TNF Therapy in Inflammatory Bowel Disease

In Crohn's disease, V/V carriers showed 100% biological response to infliximab compared to 69.8% of F carriers¹¹¹¹ V/V carriers showed 100% biological response to infliximab compared to 69.8% of F carriers, consistent with enhanced ADCC against TNF-expressing cells. Paradoxically, V/V carriers also show faster infliximab clearance and higher anti-drug antibody rates¹²¹² faster infliximab clearance and higher anti-drug antibody rates
37.5% of V/V patients developed anti-drug antibodies vs 10.6% for V/F and 5% for F/F (OR 6.08) — the same high-affinity receptor that makes the drug work better also accelerates its elimination. This creates a clinical dilemma: V/V patients may respond better initially but need closer therapeutic drug monitoring and potentially dose optimization to maintain response.

Autoimmune Disease Susceptibility

Meta-analyses link V158F to systemic lupus erythematosus susceptibility¹³¹³ Meta-analyses link V158F to systemic lupus erythematosus susceptibility
FCGR3A rs396991 shows association with SLE in recessive model (OR 1.26, p = 9.62 x 10^-5) and lupus nephritis risk, particularly in non-European populations. The enhanced IgG binding by the V allele may increase immune complex-mediated tissue damage in autoimmune conditions. In rheumatoid arthritis, the association is weaker and may interact with HLA shared epitope status¹⁴¹⁴ HLA shared epitope status
The V allele may predispose shared epitope-positive individuals to RA.

Practical Implications

The clinical significance of V158F depends heavily on context. For individuals who may receive monoclonal antibody therapy (rituximab for lymphoma, trastuzumab for breast cancer, cetuximab for colorectal cancer), knowing your genotype could inform treatment expectations and potentially guide therapeutic decisions. F/F carriers receiving these therapies may benefit from higher doses, more frequent administration, or combination approaches that don't rely solely on ADCC.

For individuals on anti-TNF therapy (infliximab, adalimumab) for inflammatory bowel disease or rheumatoid arthritis, V/V carriers should be aware of higher anti-drug antibody risk and may benefit from proactive therapeutic drug monitoring rather than reactive testing only when treatment appears to be failing.

For all carriers of the F allele, strategies that support NK cell function take on added importance since the lower-affinity receptor means each NK cell-target interaction is less efficient. While the receptor affinity is genetically fixed, NK cell number and activation state are modifiable.

Interactions

FCGR3A V158F interacts with FCGR2A rs1801274 (H131R)¹⁵¹⁵ FCGR2A rs1801274 (H131R)
Another Fc gamma receptor polymorphism affecting IgG binding, located on the same chromosome; combined low-affinity genotypes at both loci may compound reduced ADCC. In DLBCL, FCGR2A was the primary driver of survival differences — FCGR3A was not independently associated with DLBCL survival — while FCGR3A showed predictive value in follicular lymphoma settings. In autoimmune disease, the combined effect of low-affinity alleles at both FCGR3A and FCGR2A may influence susceptibility and treatment response to antibody-based therapies. Enhancer SNPs rs4656317 and rs12071048 within FCGR3A are in strong linkage disequilibrium with rs396991 and influence NK cell ADCC through transcriptional regulation of CD16a expression levels, potentially modifying the functional impact of V158F.

Biotin (vitamin B7) is indispensable for four carboxylase enzymes¹¹ carboxylase enzymes
pyruvate carboxylase, propionyl-CoA carboxylase, 3-methylcrotonyl-CoA carboxylase, and acetyl-CoA carboxylase — all require biotin as a covalently attached cofactor to function that power fat synthesis, amino acid metabolism, and gluconeogenesis. Unlike most vitamins, biotin is largely recovered from food proteins rather than absorbed free — the digestive breakdown of biotin-dependent enzymes in the diet releases biocytin²² biocytin
biotin-ε-lysine, the product of proteolytic digestion of holocarboxylases and other biotinylated proteins, which must then be cleaved back to free biotin before the body can reuse it. The enzyme responsible for this cleavage is biotinidase, encoded by the BTD gene on chromosome 3p25.1.

The rs397507173 variant introduces a c.499C>T nucleotide change that substitutes serine for proline at position 167 of the biotinidase protein (p.Pro167Ser). ClinVar records two "Likely pathogenic" submissions for this allele in the context of biotinidase deficiency, with a single "Uncertain significance" submission also on record (VCV003339734; conflicting interpretations status). The variant is absent from more than 250,000 control chromosomes in population databases, consistent with a rare disease allele. It was first documented in patients with biochemically confirmed biotinidase deficiency by Iqbal et al.³³ Iqbal et al.
Iqbal F et al. The identification of novel mutations in the biotinidase gene using denaturing high pressure liquid chromatography (dHPLC). Mol Genet Metab, 2010.

The Mechanism

Biotinidase is a member of the nitrilase superfamily. It cleaves the amide bond between biotin and lysine in biocytin, regenerating free biotin for re-attachment to newly synthesized apo-carboxylases. Without functional biotinidase, biocytin accumulates in urine (biotinuria), free biotin concentrations fall, and all four biotin-dependent carboxylases progressively lose activity. The proline at position 167 lies within the enzyme's catalytic domain; replacement with serine is predicted to disrupt local protein folding and reduce or abolish catalytic activity, consistent with ClinVar's pathogenicity assessment and in-silico tools predicting a damaging effect.

Biotinidase deficiency is classified by residual serum enzyme activity: profound deficiency (<10% of mean normal activity) causes severe neurological disease if untreated; partial deficiency (10–30% of mean normal) produces milder or stress-triggered symptoms. Heterozygous carriers typically retain ~50% of normal activity — sufficient for health under ordinary conditions but relevant for compound heterozygosity risk assessment.

The Evidence

The clinical significance of biotinidase deficiency is well established⁴⁴ well established
Wolf B. Biotinidase Deficiency. GeneReviews, 2000 (updated 2026): untreated profound deficiency causes seizures, hypotonia, developmental delay, optic atrophy, hearing loss, and alopecia, typically presenting in the first weeks to years of life. Biotin supplementation is curative if started before irreversible neurological damage occurs; some deficits (optic atrophy, sensorineural hearing loss) may not fully reverse even with treatment. Partial deficiency can remain asymptomatic for years but cause symptoms under physiological stress — intercurrent illness, pregnancy, or periods of increased biotin turnover.

The rs397507173 Pro167Ser allele itself has been reported in individuals with confirmed biotinidase deficiency, including at least one homozygous case (ClinVar record). Its rarity — absent in 251,442 control chromosomes across gnomAD datasets — and the in-silico evidence of functional disruption support the "likely pathogenic" classification. The conflicting "uncertain significance" submission likely reflects the limited published functional data specific to this single variant, rather than any evidence of benignity.

Newborn screening programs that test biotinidase activity on dried blood spots identify profound deficiency at approximately 1 in 137,000 births and combined (profound + partial) deficiency at 1 in 61,000 births⁵⁵ 1 in 137,000 births and combined (profound + partial) deficiency at 1 in 61,000 births
Wolf B, GeneReviews 2026. BTD is a required target on expanded newborn screening panels in the United States and many European countries precisely because early biotin supplementation is inexpensive, safe, and prevents irreversible harm.

Practical Actions

Heterozygous carriers (CT genotype) have sufficient biotinidase activity for normal health and do not require supplementation. The primary clinical relevance is reproductive: if both parents carry a pathogenic BTD allele, each pregnancy has a 25% probability of inheriting biallelic pathogenic variants and presenting with biotinidase deficiency. Carrier couples should receive genetic counseling before or during pregnancy.

Individuals who carry Pro167Ser in compound heterozygosity with a second pathogenic BTD variant (particularly the common profound-deficiency alleles) should have biotinidase enzyme activity measured to determine their actual activity level and need for supplementation.

For homozygous Pro167Ser (TT) individuals — an exceptionally rare genotype not yet documented in population databases — the expected clinical scenario is profound biotinidase deficiency requiring immediate and lifelong biotin supplementation, as for all confirmed profound cases.

Interactions

The key interactions for BTD pathogenic alleles involve compound heterozygosity: carrying one Pro167Ser allele together with a second BTD pathogenic variant on the other chromosome results in biallelic loss of function, producing partial or profound deficiency depending on the combined residual activity. The most common co-occurring allele in many populations is p.Asp444His (associated with partial deficiency), and the most common severe allele is the c.98_104delinsTCC frameshift. When Pro167Ser is paired with a severe loss-of-function allele, the phenotype is expected to be profound deficiency; paired with the milder p.Asp444His, the combined activity typically falls in the partial deficiency range (approximately 10–25% of normal). Any individual found to carry Pro167Ser should have their partner screened for BTD pathogenic variants before or during pregnancy, and any child of two carriers should receive biotinidase activity testing as part of newborn screening.

Cardiac myosin-binding protein C (cMyBP-C), encoded by MYBPC3 on chromosome 11, is a thick-filament accessory protein that accounts for roughly 2% of myofibrillar protein mass¹¹ roughly 2% of myofibrillar protein mass
cMyBP-C spans the C-zone of each sarcomere half and contacts both myosin and actin. Its C-terminal domains anchor it to the thick filament while its N-terminal domains regulate cross-bridge cycling — slowing myosin-actin interaction at rest and permitting contraction when phosphorylated by protein kinase A during adrenergic stimulation. MYBPC3 is the single most commonly mutated gene in hypertrophic cardiomyopathy (HCM), a condition marked by asymmetric left ventricular hypertrophy, diastolic dysfunction, and in severe cases, sudden cardiac death.

Most pathogenic MYBPC3 variants cause HCM through autosomal dominant haploinsufficiency — one defective copy is sufficient to disrupt sarcomere stoichiometry. The Gly490Val variant (rs397514752, c.1469G>T on the coding strand) is an important exception: it behaves recessively, causing disease only when both copies of MYBPC3 are affected.

The Mechanism

Glycine at position 490 falls within the C3 immunoglobulin-like domain²² C3 immunoglobulin-like domain
MYBPC3 contains 11 domains (C0-C10); C3 is an Ig-like domain in the middle segment of the protein of cMyBP-C. Glycine residues are structurally unique — their lack of a side chain allows tight turns and compact beta-strand arrangements that larger amino acids cannot adopt. Substituting the bulky valine disrupts this local fold. The conserved glycine at position 490 is present across vertebrate species, underscoring its structural importance.

In heterozygotes, one functional copy of MYBPC3 appears sufficient to maintain normal sarcomere stoichiometry, explaining why carriers remain phenotypically normal. In homozygotes, with no wild-type cMyBP-C produced, the sarcomere cannot regulate cross-bridge cycling properly, leading to the disorganized myocyte architecture (myofibre disarray) characteristic of severe HCM.

The Evidence

The variant was first reported in 2013 by Wang Y and colleagues³³ first reported in 2013 by Wang Y and colleagues
PLoS One, n=1 pedigree, 2 affected homozygous siblings, 5 unaffected heterozygous carriers, 376 controls in a consanguineous Chinese family. Both homozygous brothers presented with classic HCM: maximum wall thickness 17-18 mm, asymmetric ventricular hypertrophy on cardiac MRI, and diffuse repolarization changes with large negative T waves. None of the five adult heterozygous family members — including one aged 71 years — showed any clinical evidence of HCM by echocardiography or ECG. The variant was absent from 376 Chinese controls and public variant databases at the time of publication.

The recessive inheritance pattern at this site contrasts sharply with an adjacent variant, Gly490Arg, which causes dominant HCM. This domain-specific behavior illustrates how even nearby amino acid substitutions can produce fundamentally different inheritance modes depending on their effect on protein function versus stability.

Recessive MYBPC3 variants as a class are most dramatically illustrated by the Amish splice mutation, where homozygous infants developed lethal HCM requiring transplantation in the first year of life⁴⁴ homozygous infants developed lethal HCM requiring transplantation in the first year of life
Zahka K et al. Heart 2008; all surviving homozygous infants required cardiac transplantation, while heterozygous parents were unaffected. The Gly490Val variant appears to follow the same recessive pattern but with later onset and less catastrophic severity.

Evidence note: rs397514752 is reported in a single family (n=2 homozygous affected individuals). The evidence level is emerging — the recessive behavior is internally consistent and mechanistically plausible, but independent replication in additional families is needed before clinical management protocols can be established with confidence.

Practical Actions

For the overwhelming majority of people who carry this variant at all, the relevant question is whether they are heterozygous or homozygous. Heterozygous carriers have no current evidence of increased personal cardiac risk. Their clinical relevance lies in reproductive planning: if both members of a couple carry this variant, each pregnancy carries a 25% chance of producing a homozygous child with HCM.

Homozygous individuals warrant full cardiological evaluation given the documented severe phenotype.

Interactions

Because the pathogenic effect of rs397514752 is recessive, the key interaction is between the two copies of this variant in homozygotes — compound heterozygosity with a second MYBPC3 pathogenic variant on the other allele would likely produce a similar biallelic loss-of-function phenotype. Heterozygous carriers of rs397514752 who also carry a dominant MYBPC3 pathogenic variant on the opposite allele could theoretically have a modified phenotype, but no published evidence addresses this specific combination.

The MUC1 gene encodes mucin-1, a membrane-bound glycoprotein¹¹ membrane-bound glycoprotein
MUC1 is a large transmembrane mucin that forms a protective barrier on the surface of gastric epithelial cells that plays a crucial role in protecting the gastric lining from environmental insults, particularly the bacterium Helicobacter pylori (H. pylori)²² Helicobacter pylori (H. pylori)
H. pylori is the primary bacterial cause of gastric ulcers and gastric cancer, infecting about half the world's population. The rs4072037 variant, though synonymous³³ synonymous
A synonymous variant doesn't change the amino acid sequence but can affect mRNA splicing and gene expression, significantly affects how effectively this protective barrier functions by influencing alternative splicing of the MUC1 gene.

The Mechanism

The rs4072037 variant (G>A) is located in exon 2 of the MUC1 gene at chromosome 1q22. Though it doesn't change the encoded amino acid (making it synonymous), the A variant disrupts normal splicing patterns, leading to production of a 27-nucleotide shorter transcript⁴⁴ 27-nucleotide shorter transcript
The T allele introduces an alternative splice site that removes 27 nucleotides from the mature mRNA. This altered MUC1 protein has reduced ability to block H. pylori adhesion to gastric mucosa. The protective C allele maintains normal MUC1 structure, which more effectively blocks H. pylori adhesin binding (BabA and SabA), limiting bacterial colonization.

The Evidence

Multiple meta-analyses⁵⁵ Multiple meta-analyses
Liu et al. Meta-analysis of 9 studies with 10,410 cases and 11,437 controls have established that the C allele provides significant protection against gastric cancer, with an odds ratio of 0.70 (95% CI: 0.64-0.76). This protective effect is particularly strong in Asian populations, where the association reaches genome-wide significance. A larger meta-analysis⁶⁶ larger meta-analysis
Gu et al. 17 studies with 12,551 cases and 13,436 controls confirmed that rs4072037 is associated with decreased cancer risk, especially gastric cancer in Asian populations. An Iranian case-control study⁷⁷ Iranian case-control study
Shekarriz et al. 99 gastric cancer patients and 98 controls demonstrated a gene-environment interaction between rs4072037 genotype and H. pylori infection status in modulating gastric cancer risk.

The TT genotype is associated with approximately 2-fold increased gastric cancer risk compared to GG, and the effect is most pronounced for diffuse-type gastric cancer⁸⁸ diffuse-type gastric cancer
Diffuse gastric cancer is a more aggressive subtype with worse prognosis. Studies across multiple ethnic groups consistently show this pattern, though the effect size is larger in Asian populations (where gastric cancer and H. pylori rates are higher) than in Caucasians.

Practical Implications

If you carry one or two copies of the T allele, your gastric mucus barrier may be less effective at preventing H. pylori colonization. This doesn't mean you'll definitely develop problems, but it suggests increased vigilance around gastric health, particularly if you're in a region with high H. pylori prevalence. Consider testing for H. pylori infection if you experience persistent digestive symptoms, as early treatment can prevent progression to more serious conditions.

The protective C allele has a global frequency of approximately 45-46%, meaning that a substantial portion of the population benefits from enhanced natural defense against H. pylori. Those with CC genotype have the strongest protective effect, but even GA carriers show intermediate protection compared to AA individuals.

Interactions

The rs4072037 variant's effect is most pronounced in the presence of H. pylori infection, demonstrating a critical gene-environment interaction. The variant also exists in linkage disequilibrium⁹⁹ linkage disequilibrium
Linkage disequilibrium means these variants are often inherited together as a block with other MUC1 variants including rs2070803 and rs2075570, which also affect gastric cancer risk. The combined effect of multiple MUC1 variants may further modulate gastric mucosal protection, though individual risk from rs4072037 is well-established independent of other variants.

Ghrelin does far more than signal hunger. When it docks onto GHSR-1a (growth hormone secretagogue receptor)¹¹ GHSR-1a (growth hormone secretagogue receptor)
The canonical ghrelin receptor, expressed in the pituitary gland, hypothalamus, and across peripheral tissues. Named for its original discovery as the receptor mediating growth hormone secretion in response to synthetic GH secretagogues., it triggers a powerful pulse of growth hormone release from the pituitary. That GH pulse drives the liver to secrete IGF-1 (insulin-like growth factor 1)²² IGF-1 (insulin-like growth factor 1)
The primary mediator of GH's anabolic effects: stimulates muscle protein synthesis, promotes linear bone growth, and regulates fat metabolism. Circulating IGF-1 levels closely track GH secretion patterns over hours to days., and IGF-1 is the hormone that actually builds lean tissue — muscle, bone, connective tissue. rs509035 is an intronic variant within the GHSR gene itself, sitting at chromosome 3:172,445,659 (GRCh38). It does not change the receptor's amino acid sequence, but GWAS data from populations totalling hundreds of thousands of individuals shows that the A allele is associated with higher fat-free mass, greater adult stature, and elevated serum IGF-1 — the three expected downstream consequences of enhanced GHSR-mediated GH pulsatility.

The Mechanism

rs509035 sits within an intron of GHSR, likely in a regulatory element that influences how efficiently the gene is transcribed or the mRNA is processed. The exact molecular function has not been characterized by gel-shift or reporter assays (unlike the functionally annotated nearby promoter variant rs490683), so the mechanism is inferred from the downstream phenotype pattern rather than direct biochemical evidence. The convergence of three independent large GWAS signals — lean body mass, height, and IGF-1 — pointing to the same A allele strongly implies that A tracks with modestly elevated GHSR expression or activity, producing more frequent or larger GH pulses, more IGF-1, and consequently more lean tissue accretion over a lifetime.

Animal model support comes from studies of GHSR knockout mice³³ GHSR knockout mice
Labarthe et al. 2022 (PMID 33774644): GHS-R1a deletion reduced pulsatile GH secretion, decreased linear growth, and reduced hypothalamic GHRH mRNA expression in males — demonstrating that GHSR is causally required for normal GH pulsatility and growth., which show reduced GH pulsatility and impaired linear growth when the receptor is absent. If loss of GHSR reduces lean mass and growth, it follows that variants that enhance GHSR signaling would move these phenotypes in the opposite direction — and rs509035-A appears to do exactly that at the population level.

The Evidence

The strongest evidence comes from a sex-stratified GWAS in the UK Biobank by Hübel et al. 2019⁴⁴ Hübel et al. 2019
Genomics of body fat percentage may contribute to sex bias in anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet. 2019;180(3):222-235. N=155,961 healthy UK Biobank participants., which identified rs509035 as a genome-wide significant hit for fat-free mass (overall beta = 0.188, p = 2×10⁻¹⁵; males beta = 0.214, p = 1×10⁻⁸; females beta = 0.151, p = 5×10⁻⁹). The effect is present in both sexes but is modestly larger in men, consistent with the testosterone–GH axis interaction in lean mass regulation.

Height GWAS results from Wood et al. 2014⁵⁵ Wood et al. 2014
Nature Genetics, N=253,288 adults; the A allele (frequency 0.316) shows beta = 0.031 SD per allele, p = 3×10⁻²³. confirm that the lean mass signal has a growth axis explanation — the same allele that promotes lean tissue accretion also produces slightly greater adult height.

The CHARGE Consortium IGF-1 meta-analysis by Teumer et al. 2016⁶⁶ Teumer et al. 2016
Aging Cell, N=30,884 European adults; rs509035 A allele associated with higher serum IGF-1, p = 2×10⁻⁸. provides the mechanistic link: the A allele is associated with higher circulating IGF-1, which is the molecular effector translating GH pulsatility into lean tissue construction. Together, these three GWAS signals (fat-free mass, height, IGF-1) form a coherent picture of enhanced GHSR-to-GH-to-IGF-1 anabolic signaling in A allele carriers.

Glucose and insulin metabolism may also be modified. In the Finnish Diabetes Prevention Study (Mager et al. 2008, N=507), rs509035 was associated with several glucose and insulin measures during 3-year follow-up⁷⁷ rs509035 was associated with several glucose and insulin measures during 3-year follow-up
Mager U et al. PLoS One. 2008;3(8):e2941. The paper studied 7 GHSR SNPs in overweight adults with impaired glucose tolerance; rs509035 and rs490683 were the two variants showing significant metabolic associations., though the specific direction and magnitude of the effect for rs509035 were not separately published in the abstract. IGF-1 itself has insulin-sensitizing effects at the receptor level, so the higher IGF-1 in A allele carriers may partially explain glucose metabolism differences.

Practical Actions

For GG individuals (the majority), the GHSR intronic variant confers typical lean mass accrual potential without the enhanced GH-axis signaling that A allele carriers appear to have. For those pursuing body composition goals, the GG genotype means that lean mass gains depend primarily on training stimulus and protein adequacy rather than a genetically elevated IGF-1 floor. Monitoring IGF-1 levels is more informative for AA individuals than GG individuals, as the GG baseline is uncharacterized relative to the A allele effect.

For A allele carriers (AG and AA), enhanced GHSR-mediated GH pulsatility confers a measurable lean mass and IGF-1 advantage. This is actionable in resistance training contexts: a higher IGF-1 floor generally means faster muscle protein synthesis recovery and potentially better hypertrophic response to resistance training. Adequate protein intake (1.6–2.2 g/kg body weight daily) is necessary to fully leverage the elevated anabolic signaling environment.

Interactions

rs509035 is an intronic variant in the same GHSR gene as the promoter variants rs490683 and rs9819506, which have independent associations with appetite drive and body weight change during dietary intervention. The functional NF-1 binding site variant rs490683 (promoter) affects ghrelin receptor expression level; rs509035 (intronic) appears to operate through a downstream mechanism influencing the GH/IGF-1 anabolic axis more than appetite per se. Individuals carrying rs490683-GG (elevated appetite drive) combined with rs509035-AA (elevated IGF-1) may have a phenotype characterized by both high appetite and efficient lean tissue accretion — the genetic profile of a mesomorphic body type that gains muscle readily but also experiences strong hunger during caloric restriction.

Uterine fibroids (leiomyomas) affect an estimated 70–80% of women by age 50 and are among the leading indications for hysterectomy worldwide. The mechanisms underlying fibroid development involve a combination of estrogen sensitivity, dysregulated proliferation, and — increasingly recognised — oxidative stress and mitochondrial dysfunction¹¹ oxidative stress and mitochondrial dysfunction
Reactive oxygen species (ROS) promote smooth muscle cell proliferation and extracellular matrix deposition, both hallmarks of fibroid growth. SIRT3 sits at the centre of the mitochondrial antioxidant network, and variants that may alter its expression or activity could modestly shift the threshold for fibroid formation in susceptible women.

SIRT3 (Sirtuin 3) is the principal NAD⁺-dependent protein deacetylase²² NAD⁺-dependent protein deacetylase
SIRT3 removes acetyl groups from lysine residues on mitochondrial proteins, activating enzymes involved in energy metabolism and antioxidant defence inside mitochondria. Its major substrates include MnSOD2 (the primary mitochondrial superoxide scavenger), IDH2 (which regenerates the NADPH needed to recycle glutathione), and complexes of the electron transport chain. When SIRT3 activity is adequate, mitochondrial ROS remain controlled; when SIRT3 is reduced, ROS accumulate and can drive cell proliferation and fibrosis — two defining features of fibroid growth.

The Mechanism

rs547025 is located in intron 6 of SIRT3 on chromosome 11p15.5, within a gene region that contains a characterised enhancer variable-number tandem repeat (VNTR) in intron 5. While rs547025 itself sits approximately 128 bp into the intron adjacent to exon 3 in some transcripts (HGVS: c.280+128A>G on the coding strand), the broader SIRT3 locus contains regulatory elements capable of allele-specific variation in transcriptional efficiency. The intronic location and the protective signal of the C allele are consistent with a regulatory mechanism in which different alleles at or near rs547025 alter the binding affinity of transcription factors — potentially GATA2 or AP-1 family members that have been shown to act on the nearby SIRT3 intron-5 VNTR enhancer — thereby modulating SIRT3 expression levels³³ modulating SIRT3 expression levels
The intron-5 VNTR of SIRT3 has allele-specific enhancer activity demonstrated in transfection experiments; alleles lacking enhancer repeat units show reduced SIRT3 transcription.

The link to fibroid tissue is directly supported by protein-expression data: normal myometrial tissue expresses substantially higher SIRT3 protein than matched uterine fibroid tissue in the same women. When SIRT3 is activated pharmacologically in human leiomyoma (HuLM) cells, proliferation and collagen deposition are selectively suppressed, while normal uterine smooth muscle (UTSM) cells are unaffected — indicating that lower SIRT3 expression is a feature of, and may contribute to, the fibroid phenotype⁴⁴ lower SIRT3 expression is a feature of, and may contribute to, the fibroid phenotype
Conference abstract, Fertility & Sterility 2020: honokiol (a SIRT3 activator) inhibits HuLM leiomyoma cell growth selectively while UTSM cells resist treatment at all tested doses.

A parallel line of evidence comes from the myometrium during parturition: SIRT3 expression falls sharply in term laboring myometrium relative to non-laboring myometrium, and SIRT3 knockdown in primary myometrial cells amplifies NF-κB signalling, driving production of pro-inflammatory cytokines (IL-6, CXCL8), prostaglandins (via PTGS2), and matrix metalloproteinases. The same NF-κB and ROS-driven inflammatory programme is implicated in fibroid growth⁵⁵ is implicated in fibroid growth
Lim et al. 2016, Biology of Reproduction.

The Evidence

The primary evidence linking rs547025 specifically to fibroid risk comes from a case-control study of 737 Central Russian women with ultrasound-confirmed uterine fibroids and 451 controls⁶⁶ case-control study of 737 Central Russian women with ultrasound-confirmed uterine fibroids and 451 controls
Ponomareva, Kobzeva, Bushueva et al. Front Biosci (Schol Ed), 2024. PMID 39736018. Probe-based PCR was used to genotype seven GWAS-significant SNPs. The C allele of rs547025 was associated with a statistically significant reduction in fibroid risk in the overall cohort (OR = 0.61, 95% CI 0.43–0.87, p = 0.005), placing it among the strongest single-locus protective associations in the panel. Subgroup analyses revealed that protection was most pronounced in women with normal fruit and vegetable intake (OR = 0.39, 95% CI 0.21–0.75, p = 0.002), no prior spontaneous abortions (OR = 0.48, 95% CI 0.33–0.70, p = 0.0001), and no prior pelvic inflammatory disease (OR = 0.55, 95% CI 0.38–0.80, p = 0.002), pointing to gene-environment interactions in which co-existing oxidative burden may attenuate the protective effect.

The broader SIRT3 locus at 11p15.5 has independently appeared in uterine fibroid GWAS datasets, and rs73392700 — an intronic SIRT3 variant identified in a multi-ancestry GWAS — showed an OR of 0.77 (95% CI 0.74–0.79, p = 1.09 × 10⁻⁵⁰) in East Asian and Central/South Asian ancestry analyses, confirming that protective variation in the SIRT3 locus for fibroids is not restricted to one population.

The evidence at the specific rs547025 locus is based on a single case-control study from a Central Russian population and has not yet been independently replicated; the evidence level is therefore rated moderate. The biological rationale is plausible and supported by functional data from fibroid tissue expression studies, but replication in independent cohorts is needed before clinical utility can be established.

Practical Implications

Carrying two copies of the common T allele (TT) removes the modest protection associated with the C allele. This does not meaningfully change population-level fibroid risk on its own — the absolute difference conferred by a single variant of this effect size is small — but it may be relevant when considered alongside other fibroid risk factors: African ancestry, nulliparity, obesity, early menarche, vitamin D deficiency, and family history.

SIRT3's primary substrate pathway (NAD⁺ → SIRT3 → MnSOD2/IDH2 → glutathione regeneration) is nutritionally modifiable: SIRT3 requires NAD⁺ as a cofactor, and NAD⁺ declines with age and metabolic stress⁷⁷ NAD⁺ declines with age and metabolic stress
The SIRT3/NAD⁺ axis is a recognised mechanism for age-related mitochondrial dysfunction and a target of active supplementation research | Weir et al. 2013. Maintaining adequate NAD⁺ precursor intake (via dietary sources or supplementation) may partially compensate for reduced SIRT3 activity in TT carriers, though direct evidence specific to fibroid outcomes is not yet available.

Interactions

rs7986407 (FOXO1, 13q14.11): FOXO1 is a decidualization marker downstream of estrogen receptor signalling, and the rs7986407 locus reached genome-wide significance for fibroid risk (OR ≈ 1.09, p = 1.2 × 10⁻¹¹) in UK Biobank GWAS. Both rs547025 (SIRT3) and rs7986407 (FOXO1) were included in the Ponomareva 2024 panel. SIRT3 and FOXO1 operate on converging pathways: SIRT3 deacetylates and activates FOXO3a (a related FOXO family member), which in turn upregulates MnSOD2. FOXO1 similarly controls oxidative stress gene expression in uterine stroma. Women carrying both the SIRT3 T allele (reduced mitochondrial antioxidant protection) and a risk allele at rs7986407 (disrupted FOXO1-driven decidualization and redox control) may experience additive impairment of the dual mitochondrial-nuclear antioxidant axis in uterine tissue.

Compound action proposal for supervisor: women carrying TT at rs547025 (SIRT3) and who also carry a risk allele at rs7986407 (FOXO1, 13q14.11) may have additive impairment of mitochondrial and FOXO-driven antioxidant defence in uterine smooth muscle. The combined recommendation would be enhanced monitoring for fibroid development (annual pelvic ultrasound from age 30 in symptomatic women) and targeted optimisation of the NAD⁺/SIRT3 axis (NAD⁺ precursor supplementation at evidence-supported dosages). Evidence level: emerging (pathway convergence, single association study, no formal published gene-gene interaction analysis for this specific pair).

Every immune response needs a brake. T-cell protein tyrosine phosphatase — known as TC-PTP, encoded by PTPN2 — is one of the body's primary molecular brakes on the JAK-STAT signaling cascade¹¹ JAK-STAT signaling cascade
Janus kinase–signal transducer and activator of transcription: a core cytokine signaling pathway that controls immune cell proliferation, differentiation, and inflammation. The rs559406 variant is an intronic SNP in the PTPN2 gene on chromosome 18. Its G allele — the reference allele in the human genome — is associated with subtly reduced TC-PTP function, amplified cytokine signaling, and increased susceptibility to psoriasis and related inflammatory conditions. The T allele confers lower risk.

The Mechanism

TC-PTP removes activating phosphate groups from JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5 — the very proteins that translate cytokine receptor signals into inflammatory gene transcription. When TC-PTP activity is reduced, these kinases and transcription factors remain phosphorylated longer, sustaining inflammatory responses well past the point where they should resolve. In T cells specifically, this translates to enhanced Th1 differentiation, expanded cytotoxic CD8+ responses, and impaired regulatory T-cell (Treg) maintenance — three converging forces toward autoimmunity.

The intronic location of rs559406 suggests it influences PTPN2 expression or mRNA splicing rather than protein structure directly, a pattern consistent with other PTPN2 variants in strong linkage disequilibrium at this locus (including rs1893217²² rs1893217
An intronic PTPN2 variant in perfect LD with rs2542151, the primary IBD susceptibility SNP at this locus; same gene region, different LD block from rs559406). The specific functional consequence of the rs559406 G allele at the molecular level has not yet been characterized in published studies; the risk designation rests on genome-wide association data.

The Evidence

A genome-wide association study from the VA Million Veteran Program — one of the largest genetic studies ever conducted (>635,000 participants) — identified rs559406-G as a genome-wide significant risk allele for psoriasis³³ identified rs559406-G as a genome-wide significant risk allele for psoriasis
GCST90476186/90476190; G allele beta ≈0.073, p ≈1×10⁻¹¹; ~16,700 psoriasis cases vs ~430,000 controls, European ancestry. The modest beta coefficient (≈0.073 on a log-odds scale) corresponds to an odds ratio of approximately 1.08 per G allele — a small but population-relevant effect.

Functional studies at the gene level help explain why PTPN2 variants influence autoimmune disease. In a mouse model of type 1 diabetes, T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome⁴⁴ T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome
Mice lacking PTPN2 only in T cells showed substantially higher T1D incidence; CD8+ T-cell PTPN2 loss alone was sufficient to drive beta-cell destruction. In human pancreatic beta cells, silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%⁵⁵ silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%
Mechanism: increased JNK1 and BIM phosphorylation drives apoptosis; blocking JNK1 or BIM restored survival, identifying beta-cell protection as a direct function of TC-PTP activity. In intestinal epithelial cells, the CD-associated PTPN2 variant rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion⁶⁶ rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion
Impaired muramyl-dipeptide-induced autophagy in both intestinal epithelial cells and monocytes carrying the risk genotype, demonstrating how a slight reduction in phosphatase activity can tip the immune balance toward chronic inflammation.

At the clinical level, PTPN2 variants at this locus predict response to targeted therapies. The closely related intronic variant rs1893217 (in the same gene region, in linkage disequilibrium with rs2542151) showed that in the Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)⁷⁷ Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)
Significant association between PTPN2 C-allele carrier status and anti-TNF treatment success in both CD and UC. A separate study found that the PTPN2 rs7234029 risk allele was associated with substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease⁸⁸ substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease
89.9% nonresponse in risk allele carriers vs 67.6% in non-carriers (p=0.005), illustrating how PTPN2 genotype can guide biologic selection.

Practical Actions

Carrying the rs559406 G allele — particularly two copies — reflects a JAK-STAT signaling system that runs slightly hotter than average. The clinical consequence depends heavily on cumulative immune burden: other genetic risk factors, infection history, microbiome composition, and environmental stressors all interact with this baseline. For people who already have psoriasis or another autoimmune condition associated with JAK-STAT overactivation, the PTPN2 variant has actionable pharmacogenomic implications — JAK inhibitors (tofacitinib, upadacitinib, baricitinib) target the exact pathway that TC-PTP normally dampens, and preliminary evidence suggests PTPN2 risk carriers may have heightened responsiveness to these therapies.

For people with inflammatory bowel disease, PTPN2 genotype at this locus appears to predict biologic response patterns that can guide prescribing — though the evidence is currently at the literature/gene-association level, not formal CPIC/DPWG guideline status.

Interactions

PTPN2 functions synergistically with PTPN22 (rs2476601, R620W), which encodes a related phosphatase active in lymphocyte receptor signaling. Both genes act as negative regulators of T-cell activation — PTPN2 through JAK-STAT, PTPN22 through TCR signaling — and carrying risk variants in both simultaneously creates a broader impairment of immune braking. Reviews of PTPN2/PTPN22 combined risk have noted additive effects on T1D and IBD susceptibility, suggesting that evaluating both variants together provides a more complete picture of autoimmune risk than either alone.

Intronic PTPN2 variants at this locus may also interact with JAK-pathway modifying variants in cytokine receptor genes (IL2RA, IL7R, IL21R). The IBD literature has documented epistasis between PTPN2 rs2542151 and autophagy gene ATG16L1 rs2241879 (p=0.024), suggesting convergent effects on mucosal homeostasis when both pathways are impaired.

The TNFAIP3 gene at chromosome 6q23.3 encodes A20, the central negative regulator of NF-κB inflammatory signaling. Multiple independent genetic signals cluster at this locus, each tagging different disease susceptibilities and haplotypes — but not all signals confer the same risks. rs610604, an intronic variant sitting inside TNFAIP3 itself (rather than in the upstream intergenic region), marks the primary psoriasis susceptibility haplotype¹¹ primary psoriasis susceptibility haplotype
Nair et al. 2009 identified rs610604 as the most significant TNFAIP3 signal for psoriasis in a genome-wide scan of 1,409 psoriasis cases and 1,436 controls, followed up in 5,048 cases and 5,041 controls at this locus. Critically, this psoriasis haplotype is genetically distinct from the rheumatoid arthritis and lupus signals at the same locus — a finding with direct clinical implications.

The Mechanism

rs610604 sits in intron 6 of TNFAIP3 and does not alter the A20 protein sequence. Its biological effect is regulatory: RegulomeDB annotation²² RegulomeDB annotation
RegulomeDB scores transcription factor binding evidence and chromatin accessibility; score 4 indicates TF binding plus DNase hypersensitivity, consistent with an active regulatory region assigns this variant a score of 4, indicating evidence of transcription factor binding plus open chromatin — the molecular signature of a functional intronic regulatory element. The G allele of rs610604 likely modulates TNFAIP3 expression in keratinocytes or skin-resident immune cells in a tissue-specific manner, in contrast to the upstream regulatory variants rs6920220 and rs10499194 that primarily affect A20 levels in synovial and hematopoietic cells.

A20 functions as a dual ubiquitin-editing enzyme³³ dual ubiquitin-editing enzyme
A20 has both deubiquitinase (OTU domain) and E3 ubiquitin ligase (zinc finger domain) activities, enabling it to simultaneously remove activating ubiquitin chains from RIP1 and attach inhibitory chains to TRAF6, shutting down NF-κB signaling through two independent enzymatic steps. When A20 regulatory function is perturbed in skin tissue, NF-κB-driven cytokine production persists, promoting the Th17/IL-23 inflammatory axis characteristic of psoriasis rather than the anti-citrullinated protein antibody-driven response typical of RA.

The Evidence

The Nair et al. 2009 genome-wide scan⁴⁴ Nair et al. 2009 genome-wide scan
Published in Nature Genetics, February 2009 identified rs610604 as the lead TNFAIP3 signal for psoriasis (P=9×10⁻¹², OR=1.19), confirming TNFAIP3 alongside TNIP1 as the NF-κB pathway susceptibility locus for psoriasis. Both genes act downstream of TNF-α in the same negative-feedback loop, explaining why psoriasis — a disease driven by TNF-α and NF-κB activity in skin — is sensitive to genetic variation at this locus.

A meta-analysis of 13 case-control studies⁵⁵ meta-analysis of 13 case-control studies
13,908 psoriasis cases and 20,051 controls across European, Asian (Chinese, Indian, Pakistani), African (Egyptian), and American cohorts confirmed the association: G vs T OR=1.19 (95% CI 1.09–1.31, P=0.0002). The association holds across ancestry groups, though the G allele frequency varies substantially — common in African populations (~63%), intermediate in European (~33%) and South Asian (~32%) populations, and rare in East Asians (~8%). This pattern means the locus contributes differentially to psoriasis risk burden across populations.

A key insight from meta-analysis of the TNFAIP3 region in five European psoriasis cohorts⁶⁶ meta-analysis of the TNFAIP3 region in five European psoriasis cohorts
4,704 cases and 7,805 controls from UK, Swedish, and other European ancestry cohorts is that the psoriasis risk haplotype is categorically distinct from the autoimmune haplotypes associated with RA, SLE, and systemic sclerosis at the same locus. Haplotypes that are risk-conferring in SLE are actually protective in psoriasis, and vice versa. This means carrying the rs6920220 A allele (RA/SLE risk) does not compound psoriasis risk from rs610604 — these are independent signals marking different disease pathways through the same gene.

Practical Actions

The G allele at rs610604 confers modest but replicated psoriasis susceptibility (OR ~1.19 per allele). For GT and GG carriers who have or develop psoriasis, the most clinically actionable finding is the TNF inhibitor response prediction⁷⁷ TNF inhibitor response prediction
Michigan cohort of 432 psoriasis patients: GG genotype had 90.7% good response to etanercept vs 70.3% for TT; meta-analysis OR=1.64 for etanercept, OR=1.50 for all TNF blockers combined. G allele carriers are substantially more likely to respond well to etanercept and other TNF inhibitors — information worth sharing with a dermatologist before biologic selection.

For carriers without active psoriasis, the variant indicates modestly elevated NF-κB inflammatory tone in skin. Minimizing known psoriasis triggers — Koebner phenomenon (skin trauma), streptococcal infections, rapid withdrawal of systemic corticosteroids, certain medications (lithium, beta-blockers, antimalarials) — is particularly relevant. Maintaining serum 25(OH)D above 40 ng/mL supports skin barrier function and immune regulation; the VITAL trial⁸⁸ the VITAL trial
25,871 participants; vitamin D 2,000 IU/day reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) provides the strongest randomized evidence for vitamin D's anti-inflammatory benefit in autoimmune-susceptible individuals.

Interactions

rs610604 tags a psoriasis-specific haplotype that is genetically and functionally distinct from the other TNFAIP3 variants in this database. The RA and SLE risk signals — rs6920220 (upstream regulatory, reduces A20 expression) and rs2230926 (F127C missense, impairs A20 enzymatic activity) — operate through different mechanisms and their risk haplotypes are not concordant with the psoriasis haplotype. Carrying risk alleles at both rs6920220 and rs610604 does not represent straightforward compound risk; the two signals may actually tag opposing haplotypes.

TNIP1 (encoded by TNIP1, also called ABIN-1) works directly with A20 in the same NF-κB feedback pathway: A20 recruits TNIP1 as a scaffolding partner to terminate NF-κB signaling. The TNIP1 variant rs17728338 is also a psoriasis susceptibility SNP — identified in the same Nair 2009 GWAS — and rs610604 G carriers who also carry the rs17728338 risk allele may face compounded psoriasis risk through dual impairment of the A20-TNIP1 complex.

The IL23A locus variant rs2066808 represents the parallel IL-23 pathway susceptibility in psoriasis. Both the NF-κB pathway (TNFAIP3/TNIP1) and the IL-23 signaling axis (IL23A/IL23R/IL12B) converge on Th17 cell activation in psoriatic skin lesions.

TACI (Transmembrane Activator and CAML Interactor) is a receptor on B cells that functions as a critical switch for antibody class switching and the production of T-independent antibody responses. When TACI binds its natural ligands — BAFF and APRIL¹¹ BAFF and APRIL
B-cell Activating Factor and A Proliferation-Inducing Ligand, both members of the TNF superfamily expressed by innate immune cells; BAFF is also called BLyS (B Lymphocyte Stimulator) — it activates NF-κB signaling inside B cells, driving them to switch from producing IgM to producing IgG and IgA. The A181E variant (rs72553883) introduces a glutamic acid in place of alanine at position 181, disrupting the transmembrane domain of the protein where this intracellular signaling is coordinated. The result is a TACI receptor that can bind its ligands but cannot relay the activation signal — leaving B cells unable to mount normal class-switching responses.

The Mechanism

Unlike the related C104R variant²² C104R variant
rs34557412 (p.Cys104Arg) — a different TNFRSF13B mutation that disrupts ligand binding itself, found in 4–5% of CVID patients; A181E and C104R together account for over 90% of CVID-associated TNFRSF13B variants, the A181E protein reaches the B-cell surface and binds BAFF and APRIL normally. The problem lies downstream: the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation³³ the mutation introduces a negative glutamic acid residue into the transmembrane domain, disrupting constitutive and ligand-induced NF-κB activation
Fluorescence resonance energy transfer studies show impaired intracellular domain clustering; NF-κB response to APRIL stimulation is undetectable in cells expressing A181E vs. dose-dependent response in wildtype. This impairs the intracellular clustering of TACI's cytoplasmic domain that normally assembles signaling complexes with CAML and TRAF6.

Heterozygous carriers of A181E show elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells⁴⁴ elevated frequencies of polyreactive and anti-nuclear antibodies in new emigrant and transitional B cells
These autoreactive B cells are normally culled in the bone marrow through central tolerance; A181E heterozygotes show elevated polyreactive and ANA-positive B cells at a stage where wildtype TACI hemizygotes do not — suggesting A181E protein exerts dominant-negative effects on wildtype TACI, which is not seen in individuals who simply lack one functional TACI copy (hemizygotes). This distinction suggests that the A181E protein actively interferes with normal TACI function rather than merely reducing its quantity — making the mechanism closer to dominant-negative than to simple haploinsufficiency.

The Evidence

The founding study by Castigli et al. (2005)⁵⁵ Castigli et al. (2005)
First demonstration of TNFRSF13B mutations in CVID; B cells from carriers failed to produce IgG or IgA after APRIL stimulation despite normal surface TACI expression established that TACI mutations prevent B cells from producing IgG and IgA in response to APRIL, even when surface receptor expression and ligand binding appear intact. Among 564 patients with antibody deficiency, A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)⁶⁶ A181E was found in 13 patients (2.3%) versus 7 of 675 controls (1.0%)
C104R showed stronger enrichment: 26 patients (4.6%) vs 6 controls (0.9%), P<0.001; A181E enrichment was not statistically significant in this specific cohort. A larger meta-analysis of 1,439 CVID patients and 3,558 controls found A181E significantly enriched in patients (OR 5.60, 95% CI 2.99–10.51) when examining well-characterized cohorts.

Murine studies with the A181E equivalent mutation A144E⁷⁷ A181E equivalent mutation A144E
Human position 181 = murine position 144; the transmembrane domain is structurally conserved; the A144E mutation in mice reproduces the human A181E biochemical phenotype including impaired NF-κB activation confirmed that transgenic mice carrying this mutation had significantly reduced serum IgA levels, impaired IgG1 responses to polysaccharide antigens, and reduced B-cell proliferation in response to APRIL — closely mirroring what is observed in human A181E carriers.

Clinical data show that heterozygous carriers present across a spectrum: from fully healthy individuals to those with selective IgA deficiency, to overt CVID with recurrent sinopulmonary infections. The index case in the original TACI/A181E literature presented with recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis⁸⁸ recurrent pneumonia, otitis media, and chronic Haemophilus influenzae sinusitis
Classic pattern of T-independent antibody deficiency: encapsulated bacteria (H. influenzae, Streptococcus pneumoniae) that normally require polysaccharide-specific IgA and IgG2 for mucosal clearance. A key clinical nuance: monoallelic (heterozygous) A181E carriers show higher rates of autoimmune manifestations — particularly thrombocytopenia and lymphoproliferation — compared to biallelic carriers, who tend toward pure antibody deficiency with paradoxically lower autoimmunity rates.

Practical Implications

The A181E variant is rare globally (approximately 0.5% allele frequency) but clinically significant when present. Most heterozygous carriers have near-normal immunoglobulin levels and no obvious immunodeficiency. The variant functions as a susceptibility allele that requires additional genetic or environmental cofactors to manifest as overt disease. However, a subset of carriers — particularly those with concurrent infections, autoimmune triggers, or additional immune-related variants — may develop measurable immune dysfunction.

Monitoring serum IgG, IgA, and IgM levels provides the most direct readout of TACI function. IgA is particularly sensitive, since TACI-dependent class switching to IgA at mucosal surfaces is a key APRIL-driven function. Vaccination response testing with unconjugated pneumococcal polysaccharide (PPV23) — which activates T-independent IgG2/IgA responses through the same pathway TACI controls — provides a functional measure of whether the variant is causing clinically meaningful B-cell impairment.

Interactions

A181E interacts with the related C104R variant (rs34557412) in compound heterozygosity. Compound A181E/C104R heterozygotes show a more penetrant antibody deficiency phenotype than simple monoallelic carriers. Among patients with biallelic mutations (including compound heterozygotes), the clinical picture typically consists of pure hypogammaglobulinemia with relatively lower autoimmunity burden, while monoallelic A181E carriers show paradoxically higher rates of autoimmune manifestations including thrombocytopenia and lymphoproliferation. This distinction has been attributed to the dominant-negative mechanism of A181E, which — even in the heterozygous state — disrupts wildtype TACI's role in central B-cell tolerance.